(1) 基于肿瘤细胞特定的氨基酸代谢特征开展小分子靶向药物及探针的研究；
(2) 肿瘤及炎症相关丝氨酸/苏氨酸激酶抑制剂的发现研究；
(3) 小分子免疫调控剂创新药物的研发与产业化

1、科研项目
（1）国家自然科学基金委员会，面上项目，82073702，基于结构的GLS1变构抑制剂的设计、合成及抗恶性肿瘤活性研究，2021-01-01至2024-12-31，55万元，在研，主持
（2）国家自然科学基金委员会，青年科学基金项目，81703347，基于细胞自组装蛋白水解靶向嵌合体策略设计新型CDK9小分子调控剂，2018-01-01至2020-12-31，20万元，结题，主持
（3）江苏省科技厅，靶向肿瘤谷氨酰胺代谢的创新药物的发现与成药性评价，基础研究计划（自然科学基金）--优秀青年基金项目，BK20211580，2021-07 至 2024-06，50万元，主持
（4）江苏省科技厅，基于蛋白降解靶向嵌合体策略构建CDK9小分子调控剂的研究，基础研究计划（自然科学基金）--青年基金项目，SBK2017041384，2017-07 至 2020-06，20万元，主持
2、专利转化
​ （1）化药1类创新药物新型JAK抑制剂，专利成果转化，一又生物（上海）有限公司，5000万元，2022-07

1. Wen Li, Jiali Huang, Chen Shen, Weiye Jiang, Xi Yang, Jingxuan Huang, Yueqing Gu, Zhiyu Li*, Yi Ma*, Jinlei Bian*, Tumor-targeted metabolic inhibitor prodrug labelled with cyanine dyes enhances immunoprevention of lung cancer. Acta Pharmaceutica Sinica B, 2023, accepted. (IF: 14.903)
2. Tizhi Wu, Bin Yu, Yifan Xu, Zekun Du, Zhiming Zhang, Yuxiao Wang, Haoming Chen, Li Ao Zhang, Rui Chen, Feihai Ma, Weihong Gong, Sixian Yu, Zhixia Qiu, Hongxi Wu, Xi Xu, Jubo Wang*, Zhiyu Li*, Jinlei Bian*, Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung Cancer. Journal of Medicinal Chemistry, 2023, doi: 10.1021/acs.jmedchem.3c01400. (IF: 7.3)
3. Li Zhou, Bin Yu, Mengqiu Gao, Rui Chen, Zhiyu Li, Yueqing Gu, Jinlei Bian*, Yi Ma*, DNA framework-engineered chimeras platform enables selectively targeted protein degradation. Nature Communications, 2023, 14: 4510. (IF: 16.6)
4. Dongyu Liu, Bin Yu, Xin Guan, Bin Song, Huikai Pan, Renbing Wang, Xi Feng, Lixia Pan, Huidan Huang, Zhe Wang, Hongxi Wu, Zhixia Qiu, Zhiyu Li*, Jinlei Bian*, Discovery of a photoactivatable dimerized STING agonist based on the benzo[b]selenophene scaffold. Chemical Science, 2023, 14: 4174-4182. (IF: 8.4)
5. Xi Feng, Lixia Pan, Zhiyu Qian, Dongyu Liu, Xin Guan, Li Feng, Bin Song, Xi Xu, Ninghua Tan, Yi Ma, Zhiyu Li*, Zhe Wang*, Jinlei Bian*, Discovery of Selenium-Containing STING Agonists as Orally Available Antitumor Agents. Journal of Medicinal Chemistry, 2022, 65: 15048-15065. (IF: 8.039)
6. Yucheng Tian, Kang Liu, Ruoyi Liu, Zhixia Qiu, Yifan Xu, Wei Wei, Xi Xu, Jubo Wang, Hong Ding, Zhiyu Li*; Jinlei Bian*, Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer through Regulating ERα Expression. Journal of Medicinal Chemistry, 2022, 65: 8914-8932. (IF: 8.039)
7. Xi Xu#; Jubo Wang#; Min Wang; Xinyu Yuan; Lei Li; Chao Zhang; Huidan Huang; Tian Jing; Chenchen Wang; Chao Tong; Liwen Zhou; Ying Meng; Pengfei Xu; Junping Kou; Zhixia Qiu; Zhiyu Li*; Jinlei Bian*, Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site, Journal of Medicinal Chemistry, 2021, 64: 4588-4611. (IF: 8.039)
8. Zhen Qin#; Bin Dong#; Renbing Wang; Dechun Huang; Jubo Wang*; Xi Feng; Jinlei Bian*; Zhiyu Li*, Preparing anti-SARS-CoV-2 agent EIDD-2801 by a practical and scalable approach, and quick evaluation via machine learning, Acta Pharmaceutica Sinica B, 2021, 11: 3678-3682. (IF: 14.903)
9. Yucheng Tian#; Jubo Wang#; Xinying Cheng; Kang Liu; Tizhi Wu; Xiaqiu Qiu; Zijian Kuang; Zhiyu Li*; Jinlei Bian*, Microwave-assisted unprotected Sonogashira reaction in water for the synthesis of polysubstituted aromatic acetylene compounds, Green Chemistry, 2020, 22:1338-1344. (IF: 11.034)
10. Xi Xu; Zijian Kuang; Jie Han; Ying Meng; Lei Li; Hongyu Luan; Pengfei Xu; Jubo Wang; Cheng Luo; Hong Ding; Zhiyu Li*; Jinlei Bian*, Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors, Journal of Medicinal Chemistry, 2019, 62: 9642-9657. (IF: 8.039)

李志裕 教授
徐熙 副教授
王举波副教授
邱志霞副教授
吴红茜副教授
博士研究生
喻彬 （2022级）
张立翱（2023级）